Trial Profile
Phase I Bridging Trial of TG4010 as Antigen-Specific Immunotherapy in Patients With MUC-1 Positive Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs TG 4010 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 22 Nov 2012 New trial record